Delphi Genetics Grants Merck License for the Use of the StabyExpress System

Delphi Genetics SA (“Delphi”) has announced today a broad licensing agreementwith a subsidiary of Merck & Co., Inc., known as MSD outside the United Statesand Canada, for the use of the StabyExpress™ technology, which allows highyield, cost effective protein expression without the use of antibiotics.Under the agreement, Merck receives a non-exclusive license to use theStabyExpress™ technology for protein expression in research and productdevelopment. In exchange, Delphi is eligible to receive milestone paymentsassociated with the development of Merck product candidates that utilize theStabyExpress™ technology, as well as royalties on sales of such products. Thefinancial details of the agreement were not disclosed.